

Alamar Biosciences launches NULISaseq Neuro 220 Panel to advance precision R&D in neurology

March 18, 2026 | News

New panel expands coverage for Alzheimer's and Parkinson's diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and 12 assays specific to brain and peripheral Tau isoforms



Alamar Biosciences has announced the launch of the NULISaseq Neuro 220 Panel, its largest precision proteomics panel to date, designed to advance research in neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. The panel enables multiplexed measurement of 220 biomarkers from a single sample with ultra-high sensitivity and high specificity, building on the flagship NULISaseq CNS Disease Panel 120. It features new biomarker content developed with support from The Michael J. Fox Foundation (MJFF) for Parkinson's Research, including a comprehensive suite of Tau protein assays targeting brain-derived and peripheral isoforms of total tau and phosphorylated species (pTau217, pTau181, pTau205, pTau212, pTau231).

Nicole Polinski, PhD, Director of Research Programs at MJFF, emphasized the importance of these assays in understanding disease progression and accelerating diagnostic and prognostic research. Dr. Yuling Luo, Alamar's CEO, highlighted the panel as a milestone in precision proteomics, underscoring the collaboration with MJFF to advance Parkinson's biomarker research.

The NULISaseq Neuro 220 Panel supports a wide range of neurological disorders, including frontotemporal dementia, ALS, and traumatic brain injury. Its ultra-high sensitivity and specificity enable pre-symptomatic detection and compatibility with non-invasive sample collection. Automated workflows via the ARGO™ HT System ensure reproducibility and ease of use, facilitating analysis of disease heterogeneity, co-pathologies, and therapeutic response signatures.

The panel will debut at AD/PD 2026 in Copenhagen, where Dr. Henrik Zetterberg will present its utility in neurodegenerative diseases. He noted the panel's potential to deepen understanding of disease mechanisms and accelerate therapeutic development. Additional data showcasing the NULISA platform's capabilities will be presented in over 11 oral presentations and 25 posters at the conference. This launch underscores Alamar's commitment to innovation in neurodegenerative disease research.